Suzhou-based Cure Genetics has entered into a collaboration and licensing agreement with Hong Kong’s Frametact Ltd, focusing on the development of novel adeno-associated virus (AAV) vectors for therapeutics addressing familial neurological diseases. Under the terms of the deal, Frametact will pay Cure Genetics a combined USD 60 million in upfront and milestone payments, with additional royalties on future sales. Cure Genetics will leverage its proprietary VELP platform to develop these AAV vectors.
Frametact’s Background and Focus Areas
Frametact was established by a molecular neuroscience research team from The Hong Kong University of Science and Technology and the Hong Kong Center for Neurodegenerative Diseases. The company is dedicated to researching technologies in neurobiology, neuropharmacology, and neurodegenerative diseases, with a particular focus on Alzheimer’s disease. This collaboration will combine Frametact’s expertise with Cure Genetics’ capabilities in AAV vector development and in vivo AAV screening.
Targeting Familial Neurodegenerative Diseases
The partnership aims to target familial neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and Huntington’s disease. By utilizing Cure Genetics’ VELP platform, the collaboration seeks to create innovative AAV vectors that could potentially revolutionize the treatment of these debilitating conditions.-Fineline Info & Tech
